2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAntiviral AgentsCohort StudiesHepacivirusHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosis
2020
AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, . AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020, 159: 320-334.e27. PMID: 32407808, PMCID: PMC7212965, DOI: 10.1053/j.gastro.2020.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBetacoronavirusClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingGastroenterologyGastrointestinal DiseasesGastrointestinal TractHumansLiverLiver DiseasesLiver Function TestsPandemicsPneumonia, ViralPractice Guidelines as TopicPrevalenceReferral and ConsultationSARS-CoV-2Societies, MedicalUnited StatesConceptsNausea/vomitingPooled prevalence estimatesAbdominal painLiver manifestationsGI symptomsLiver abnormalitiesCOVID-19Prevalence estimatesPractice statementsGI symptom questionnaireLiver enzyme abnormalitiesCertainty of evidencePrevalence of diarrheaCoronavirus disease 2019Best practice statementsSystematic literature searchStudy selection processFixed-effects modelNausea/Gastrointestinal symptomsLiver functionUnique patientsGRADE frameworkSubgroup analysisSymptom questionnaire
2018
An expert consensus for the management of chronic hepatitis B in Asian Americans
Tong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-viral therapyHepatocellular carcinomaHepatitis BHBV DNAPregnant womenBasal core promoter mutationsNegative chronic hepatitis BHepatitis B virus infectionAsian American physiciansLiver related deathManagement of HBVDetectable HBV DNAHBeAg-negative patientsHBsAg-positive patientsHBV DNA levelsNormal ALT levelsB virus infectionCore promoter mutationsHBsAg carrier rateLife-long surveillanceContrast CT scanAbdominal ultrasound examinationAlpha-fetoprotein testingAsian American patientsSafety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, Group H. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology And Hepatology 2018, 16: 1811-1819.e4. PMID: 29306043, PMCID: PMC6034985, DOI: 10.1016/j.cgh.2017.12.037.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsBenzimidazolesDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsEuropeFemaleFluorenesGenotypeHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLongitudinal StudiesMaleMiddle AgedNorth AmericaProspective StudiesRibavirinSofosbuvirSustained Virologic ResponseTreatment OutcomeYoung AdultConceptsTreatment-experienced patientsGenotype 1 HCV infectionAddition of ribavirinHCV infectionGenotype 1 hepatitis C virus infectionChronic genotype 1 HCV infectionHepatitis C virus infectionHCV-TARGET studyRate of SVR12Treatment-experienced adultsC virus infectionPrimary efficacy endpointGenotype 1 infectionObservational cohort studyWeeks of treatmentEnd of treatmentRoutine clinical practiceSofosbuvir treatmentVirologic outcomesVirologic responseEfficacy endpointHepatitis CProtocol populationAdverse eventsCohort study
2017
Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C
Ooka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. The American Journal Of Gastroenterology 2017, 112: 828. PMID: 28374816, DOI: 10.1038/ajg.2017.87.Peer-Reviewed Original Research
2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian durationDrug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.Peer-Reviewed Original ResearchConceptsSofosbuvir/ledipasvirViral loadMedicaid coverageChild-Pugh class B diseaseInitial approvalEnd-stage liver disease (MELD) scoreStage liver disease scoreChronic HCV infectionClass B diseaseDrug authorizationHCV care cascadeSOF/LEDAdvanced liver diseaseBaseline viral loadHepatitis C infectionLiver Disease scoreRetrospective chart reviewHigh viral loadSignificant predictorsHigher likelihoodMedicare/MedicaidSOF/C infectionCare cascadeHCV infection
2014
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 2014, 148: 215-219. PMID: 25447850, DOI: 10.1053/j.gastro.2014.10.039.Peer-Reviewed Original ResearchSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet 2014, 384: 1756-1765. PMID: 25078309, DOI: 10.1016/s0140-6736(14)61036-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis C, ChronicHeterocyclic Compounds, 3-RingHumansInterferon-alphaLiver Function TestsMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsReference ValuesRibavirinRisk AssessmentSeverity of Illness IndexSimeprevirSofosbuvirSulfonamidesTreatment OutcomeUridine MonophosphateConceptsTreatment-naive patientsAdverse eventsGroup 1Chronic HCV genotype 1 infectionHepatitis C virus genotype 1Grade 4 adverse eventsVirological response 12 weeksHCV genotype 1 infectionHepatitis C virus infectionC virus genotype 1C virus infectionCommon adverse eventsInterferon-free regimensSerious adverse eventsGenotype 1 infectionPrimary endpointWeek 12Study treatmentChronic infectionCohort 1Genotype 1Grade 3Virus infectionSafety dataAmylase concentration